Statins suppress cell-to-cell propagation of α-synuclein by lowering cholesterol
Cell Death & Disease · 2023
DOI: 10.1038/s41419-023-05977-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Death & Disease, 2023. Verfasst von Joo-Ok Min und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Neuroscience Research Institute, Convergence Research Center for Dementia, Seoul National University College of Me…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, J.-O.M received a scholarship from the BK21 FOUR education program..
Abstract (Originalsprache)
Cell-to-cell propagation of protein aggregates has been implicated in the progression of neurodegenerative diseases. However, the underlying mechanism and modulators of this process are not fully understood. Here, we screened a small-molecule library in a search for agents that suppress the propagation of α-synuclein and mutant huntingtin (mHtt). These screens yielded several molecules, some of which were effective against both α-synuclein and mHtt. Among these molecules, we focused on simvastatin and pravastatin. Simvastatin administration in a transgenic model of synucleinopathy effectively ameliorated behavioral deficits and α-synuclein accumulation, whereas pravastatin had no effect. Because only simvastatin enters the brain effectively, these results suggest that inhibition of brain cholesterol synthesis is important in simvastatin effects. In cultured cells, accumulation of intracellular cholesterol, induced by genetic ablation of the NPC1 gene or by pharmacological treatment with U18666A, increased α-synuclein aggregation and secretion. In contrast, lowering cholesterol using methyl-β-cyclodextrin or statins reversed α-synuclein aggregation and secretion in NPC1-knockout cells. Consistent with these observations, feeding a high-fat diet aggravated α-synuclein pathology and behavioral deficits in the preformed fibril-injected mouse model, an effect that was also reversed by simvastatin administration. These results suggest that statins suppress propagation of protein aggregates by lowering cholesterol in the brain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Neuroscience Research Institute, Convergence Research Center for Dementia, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.
- Interdisciplinary Program in Neuroscience, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea.
- Neuramedy Co. Ltd, Seoul, Republic of Korea.
- Nutritional Sciences and Toxicology Department, University of California Berkeley, Berkeley, CA, USA.
- ToolGen, Inc, Seoul, Republic of Korea.
- Department of Biomedical Sciences, Neuroscience Research Institute, Convergence Research Center for Dementia, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea. sjlee66@snu.ac.kr.
ORCID-Profile: Joo-Ok Min, Seung-Jae Lee
Förderung
- National Research Foundation of Korea
- J.-O.M received a scholarship from the BK21 FOUR education program.
Zitieren
APA
Min, J. O., Ho, H. A., Lee, W., Jung, B. C., Park, S. J., Kim, S., & Lee, S. J. (2023). Statins suppress cell-to-cell propagation of α-synuclein by lowering cholesterol. Cell Death & Disease. https://doi.org/10.1038/s41419-023-05977-9
Vancouver
Min JO, Ho HA, Lee W, Jung BC, Park SJ, Kim S, et al. Statins suppress cell-to-cell propagation of α-synuclein by lowering cholesterol. Cell Death & Disease. 2023. doi:10.1038/s41419-023-05977-9
BibTeX
@article{Min2023,
author = {Min, Joo-Ok and Ho, Hoang-Anh and Lee, Wonjae and Jung, Byung Chul and Park, Sung Jun and Kim, Seokjoong and Lee, Seung-Jae},
title = {Statins suppress cell-to-cell propagation of α-synuclein by lowering cholesterol},
journal = {Cell Death & Disease},
year = {2023},
doi = {10.1038/s41419-023-05977-9}
}
EUVIMED